BioAge files for IPO, riding momentum for weight loss drugs

Max Bayer

Pharma Reporter

BioAge Labs is heading to Wall Street after months of speculation that the Eli Lilly-partnered cardiometabolic biotech was planning to join the public markets. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioAge files for IPO, riding momentum for weight loss drugs

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

BioAge files for IPO, rid­ing mo­men­tum for weight loss drugs

Pharma Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

BioAge files for IPO, riding momentum for weight loss drugs